Neon Therapeutics Named a Top Place to Work in Massachusetts by The Boston Globe
The Top Places to Work awards recognize the most admired workplaces in the state, as voted on by the employees of those companies. The annual survey, now in its 11th year, measures employee opinions about their company’s direction, management, culture, pay and benefits and engagement with employees, among other factors.
Neon was ranked first among the small biotech companies surveyed and sixth overall among
“We’re especially proud of this honor because the recognition is based on accolades coming straight from our own team,” said Hugh O’Dowd, President and Chief Executive Officer of Neon. “I consider it my most important job as CEO to nurture a culture that lets every Neon employee do their best work, while building a sense of common mission. It’s wonderful to have our approach affirmed through this award.”
The Boston Globe’s rankings are based on confidential surveys collected by Energage (formerly WorkplaceDynamics), an independent company specializing in employee engagement and retention. Surveys were collected this year from more than 82,000 individuals at 318 organizations across the state. The winners share several common traits, including giving employees a voice in the workplace, cultivating a culture that makes time for fun and offering strong benefit packages.
Details about the winning companies were published online Thursday night and will appear in print in
About Neon Therapeutics
Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies, including NEO-PV-01, a clinical stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of estrogen-receptor-positive breast cancer. For more information, please visit www.neontherapeutics.com.
Stephanie Simon, Ten Bridge Communications
Will O’Connor, Stern Investor Relations
Source: Neon Therapeutics, Inc.